ClinicalTrials.gg
WithdrawnNCT04373083Updated Jan 15, 2021

Anti-PD-1 Antibody Treatment With Cemiplimab and Radiotherapy in Early-stage Classical Hodgkin Lymphoma

A Phase 2 interventional study of Cemiplimab and Involved-site radiotherapy (IS-RT) in Hodgkin Lymphoma, sponsored by Regeneron Pharmaceuticals. Withdrawn. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-01-15.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Business Decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The primary objective is to estimate the efficacy of experimental treatment with the anti-PD-1 antibody cemiplimab (REGN2810) in combination with simultaneous or subsequent radiotherapy (RT) in early-stage favorable classical Hodgkin lymphoma (cHL).

Secondary objectives are to assess the safety and feasibility of the 2 experimental strategies.

02

Conditions studied

  • Hodgkin Lymphoma

Browse trials for

Keywords

  • Early Stage
  • Favorable
  • Classical
  • classical Hodgkin lymphoma (cHL)
03

In context

Hodgkin Disease

1,383 studies on the registry are indexed under Hodgkin Disease; 163 are open to participants now.

Browse Hodgkin Disease studies →

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • proven classical HL
  • First diagnosis, no previous treatment
  • Stage I-II without risk factors as defined in the protocol

Key Exclusion Criteria:

  • Composite lymphoma or nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL)
  • Prior within the previous 5 years (except for locally treatable cancers that have been apparently cured by complete resection)
  • Prior chemotherapy or radiation therapy
  • Concurrent disease precluding protocol treatment as defined in the protocol
  • Pregnancy or breast-feeding
  • Non-compliance as defined in the protocol

Note: Other protocol-defined Inclusion/Exclusion criteria apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Concomitant treatment

    Treatment Group A

    Drug: Cemiplimab · Radiation: Involved-site radiotherapy (IS-RT)

  • Experimental
    Sequential treatment

    Treatment Group B

    Drug: Cemiplimab · Radiation: Involved-site radiotherapy (IS-RT)

Interventions

  • Administered in 3-week intervals

    Also known as: REGN2810, Libtayo

  • RadiationInvolved-site radiotherapy (IS-RT)

    Patients will receive IS-RT with a dose of 20 Gy. Involved-site radiotherapy will be carried out on the basis of 3D imaging as described in the protocol

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS) at 1 year

    Time frame: From randomization up to 1 year

Secondary outcomes

  1. PFS at 2 and 3 years

    Time frame: From randomization up to 3 years

  2. Overall survival (OS) at 1, 2, and 3 years

    Time frame: From randomization up to 3 years

  3. Incidence of acute toxicities

    Time frame: Up to 90 days after study treatment

  4. Rate of patients with long-term fatigue using EORTC-QLQ-FA12

    European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ). -FA12 module complements the core EORTC QLQ-C30 questionnaire regarding fatigue. Each item can be scored in four dimension on a scale from 1 to 4 with higher scores indicating worse symptoms.

    Time frame: 12-18 months after randomization

  5. Rate of patients with long-term fatigue using EORTC-QLQ-C30

    Scores range from 0 to 100. A high scale score represents a higher response level.

    Time frame: 12-18 months after randomization

  6. Quality of life (QoL) using EORTC-QLQ-30

    Scores range from 0 to 100. A high scale score represents a higher response level.

    Time frame: Up to 3 years

  7. Rate of early discontinuation of study treatment

    Time frame: From first dose to up to 19 weeks

  8. Frequency of lymphoma treatment administered in addition to study treatment

    Time frame: From randomization up to 3 years

  9. Types of lymphoma treatment administered in addition to study treatment

    Time frame: From randomization up to 3 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.

Access criteria: Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency [EMA], Pharmaceuticals and Medical Devices Agency [PMDA], etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2020; primary completion for Dec 2022, 25 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2020
First posted
May 4, 2020
StartEst.
Nov 15, 2020
Primary completionEst.
Dec 20, 2022
CompletionEst.
Feb 20, 2025
Last update
Jan 15, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04373083
Collaborators
Sanofi
Responsible party
Sponsor
First posted
May 4, 2020
Start date
Nov 15, 2020 (estimated)
Primary completion
Dec 20, 2022 (estimated)
Completion
Feb 20, 2025 (estimated)
Last update
Jan 15, 2021

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cemiplimab

Start the discussion